The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort

Massimo Radin, Savino Sciascia, Doruk Erkan, Vittorio Pengo, Maria G. Tektonidou, Amaia Ugarte, Pierluigi Meroni, Lanlan Ji, H. Michael Belmont, Hannah Cohen, Guilherme Ramires de Jesús, D. Ware Branch, Paul R. Fortin, Laura Andreoli, Michelle Petri, Esther Rodriguez, Ignasi Rodriguez-Pinto, Jason S. Knight, Tatsuya Atsumi, Rohan WillisEmilio Gonzalez, Rosario Lopez-Pedrera, Ana Paula Rossi Gandara, Margarete Borges Gualhardo Vendramini, Alessandra Banzato, Ecem Sevim, Medha Barbhaiya, Maria Efthymiou, Ian Mackie, Maria Laura Bertolaccini, Danieli Andrade

Research output: Contribution to journalArticle

Abstract

Objectives: To assess whether patients with antiphospholipid syndrome (APS) and history of recurrent thrombosis have higher levels of adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) when compared to patients without recurrent thrombosis. Methods: In this cross-sectional study of antiphospholipid antibody (aPL)-positive patients, we identified APS patients with a history of documented thrombosis from the AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Data on aPL-related medical history and cardiovascular risk factors were retrospectively collected. The aGAPSS was calculated at Registry entry by adding the points corresponding to the risk factors: three for hyperlipidemia, one for arterial hypertension, five for positive anticardiolipin antibodies, four for positive anti-β2 glycoprotein-I antibodies and four for positive lupus anticoagulant test. Results: The analysis included 379 APS patients who presented with arterial and/or venous thrombosis. Overall, significantly higher aGAPSS were seen in patients with recurrent thrombosis (arterial or venous) compared to those without recurrence (7.8 ± 3.3 vs. 6 ± 3.9, p<0.05). When analyzed based on the site of the recurrence, patients with recurrent arterial, but not venous, thrombosis had higher aGAPSS (8.1 ± SD 2.9 vs. 6 ± 3.9; p<0.05). Conclusions: Based on analysis of our international large-scale Registry of aPL-positive patients, the aGAPSS might help risk stratifying patients based on the likelihood of developing recurrent thrombosis in APS.

Original languageEnglish (US)
Pages (from-to)464-468
Number of pages5
JournalSeminars in Arthritis and Rheumatism
Volume49
Issue number3
DOIs
StatePublished - Dec 2019

Keywords

  • Antiphospholipid antibodies
  • Antiphospholipid syndrome
  • Cardiovascular
  • GAPSS
  • Risk stratification
  • Thrombosis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort'. Together they form a unique fingerprint.

  • Cite this

    Radin, M., Sciascia, S., Erkan, D., Pengo, V., Tektonidou, M. G., Ugarte, A., Meroni, P., Ji, L., Belmont, H. M., Cohen, H., Ramires de Jesús, G., Branch, D. W., Fortin, P. R., Andreoli, L., Petri, M., Rodriguez, E., Rodriguez-Pinto, I., Knight, J. S., Atsumi, T., ... Andrade, D. (2019). The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. Seminars in Arthritis and Rheumatism, 49(3), 464-468. https://doi.org/10.1016/j.semarthrit.2019.04.009